Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service tumor & fibroid embolization cases in Maryland: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 11% on average (118 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 6 | 316 | 14% |
| 2020 | 8 | 336 | 15% |
| 2021 | 10 | 344 | 19% |
| 2022 | 10 | 391 | 22% |
| 2023 | 10 | 355 | 25% |
| 2024 | 12 | 701 | 28% |
| 2025 from claims | – | 782 632–918 | 29% |
| 2026 forecast | – | 872 683–1,096 | 29% |
| 2027 forecast | – | 958 710–1,266 | 29% |
| 2028 forecast | – | 1,051 744–1,451 | 30% |
| 2029 forecast | – | 1,154 784–1,654 | 31% |
| 2030 forecast | – | 1,266 829–1,879 | 31% |
Chemo- and radioembolization of liver tumors, uterine fibroid and other organ embolization (one code covers all). Professional codes (what the surgeon bills): CPT 37243.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 96% of the cases CMS names in Maryland; 6 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 20% hospital outpatient, 80% office. The share outside the hospital has moved +80 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Hospital outpatient | Office |
|---|---|---|
| 2026 · ~870 | ~120 | ~750 |
| 2027 · ~960 | ~110 | ~850 |
| 2028 · ~1,100 | ~100 | ~950 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: hospital outpatient about 10% (20% in 2025), office about 90% (80% in 2025).
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 29 | 1,301+2.9%/yr | +2.9%/yr | 0.6 | 55% | 3,590 in 2030+18%/yr |
| Texas | 20 | 1,239+2.9%/yr | +2.9%/yr | 0.6 | 63% | 3,140 in 2030+17%/yr |
| Virginia | 12 | 902+21%/yr | +21%/yr | 0.9 | 55% | 2,310 in 2030+17%/yr |
| North Carolina | 11 | 795+10%/yr | +10%/yr | 0.8 | 63% | 1,900 in 2030+16%/yr |
| Tennessee | 13 | 482+8.1%/yr | +8.1%/yr | 0.7 | 71% | 1,670 in 2030+23%/yr |
| Georgia | 5 | 259−8.1%/yr | −8.1%/yr | 0.3 | 64% | 920 in 2030+23%/yr |
| Kentucky | 1 | 248+17%/yr | +17%/yr | 0.5 | 79% | 1,090 in 2030+28%/yr |
| South Carolina | 7 | 207−3.3%/yr | −3.3%/yr | 0.3 | 46% | 820 in 2030+26%/yr |
| Alabama | 5 | 198+0.2%/yr | +0.2%/yr | 0.5 | 68% | 810 in 2030+26%/yr |
| Mississippi | 6 | 194+19%/yr | +19%/yr | 0.5 | 36% | 380 in 2030+12%/yr |
| Oklahoma | 2 | 185+1.4%/yr | +1.4%/yr | 0.4 | 22% | 180 in 2030−0.6%/yr |
| Louisiana | 3 | 167−2.6%/yr | −2.6%/yr | 0.4 | 37% | 260 in 2030+7.6%/yr |
| Arkansas | 3 | 165−1.3%/yr | −1.3%/yr | 0.4 | 73% | 740 in 2030+29%/yr |
| District of Columbia | 3 | 100−4.1%/yr | −4.1%/yr | 1.6 | 87% | 160 in 2030+7.9%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Breast biopsy & localization | 79 | 5,089−2.2%/yr | −2.2%/yr | 6.00.9× | 73% | 5,630 in 2030+1.7%/yr |
| Tumor ablation | 5 | 276+7%/yr | +7%/yr | 0.31.0× | 0% | 670 in 2030+16%/yr |
Tumor & fibroid embolization in every state, and its device makers · Every procedure market in Maryland · Every state · Compare with Florida
Pulse Biosciences leads with 59% of company spending on these surgeons in 2025, +55 pts on 2024.
In 2025, 19 companies reported engagement with Maryland’s surgeons worth $1.1M in consulting, speaking, meals and travel tied to these products, about $90K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 16 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.